布鲁顿酪氨酸激酶(BTK)抑制剂在治疗炎症免疫性疾病中的研究进展  

Research progress of Bruton's tyrosine kinase(BTK)inhibitors in the treatment of inflammatory and immune-mediated diseases

作　　者：任玮杰 岑丽芳 邹毅 REN Weijie;CEN Lifang;ZOU Yi(School of Pharmacy,China Pharmaceutical University,Nanjing 211198,China)

机构地区：[1]中国药科大学药学院,南京211198

出　　处：《中国药科大学学报》2024年第1期63-72,共10页Journal of China Pharmaceutical University

摘　　要：布鲁顿酪氨酸激酶(Bruton’s tyrosine kinase,BTK)是一种胞质酪氨酸激酶,参与B细胞和粒细胞的活化,在B细胞和Fcγ受体下游发挥作用。临床前研究表明,抑制BTK活性可能成为自身免疫性疾病和过敏等炎症免疫相关病症的潜在治疗方法。本文总结了BTK在免疫相关疾病中的作用机制,并对目前临床在研的BTK抑制剂用于免疫相关疾病治疗的研究情况进行了综述,以期为BTK抑制剂在非肿瘤适应证的研究提供新思路。Bruton's tyrosine kinase(BTK),a cytoplasmic tyrosine kinase,plays a central role in the activation of B cells and granulocytes,operating downstream of B cell and Fcγreceptors,and is considered an attractive target for treating autoimmune diseases.Preclinical investigations have demonstrated that inhibition of BTK activity holds promise as a potential therapeutic strategy for inflammatory immune responses such as autoimmune diseases and allergies.This review provides an overview of the mechanisms by which BTK contributes to immune-related diseases and summarizes current research on the development of BTK inhibitors for treating these conditions,aiming to offer novel insights into non-oncology applications for BTK inhibitors.

关 键 词：布鲁顿酪氨酸激酶 炎症免疫 自身免疫性疾病 过敏 临床研究 

分 类 号：R914[医药卫生—药物化学] R593[医药卫生—药学]